beacon trial results: safety & efficacy of bitopertin in adults with epp
Published 1 year ago • 110 plays • Length 2:50Download video MP4
Download video MP3
Similar videos
-
1:45
mechanism of action of bitopertin to treat patients with epp
-
1:57
investigating the efficacy and safety of adct-602 in patients with r/r b-all
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
3:17
results from a murine model investigating bitopertin for the treatment of epp
-
2:08
inotuzumab ozogamicin & venetoclax in the treatment of b-all: findings from a phase i trial
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
3:00
five-year follow-up of the captivate trial: ibrutinib retreatment in patients with cll
-
4:04
the future of myeloma treatment and the possibility of cure
-
3:18
midiagnostics' complete blood count (cbc) - blood analysis for diagnosis and monitoring
-
5:54
thawing and plating cryoplateable hepatocytes
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml
-
2:29
the safety and feasibility of car-t & bispecifics in patients with myeloma after prior allosct
-
2:04
introducing a phase ib/ii trial to evaluate tasquinimod for the treatment of myelofibrosis
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
3:54
a case study from the ecog-e1910 trial: early blinatumomab treatment in all
-
1:30
the use of pirtobrutinib in richter's transformation: data from the bruin trial
-
1:52
maic of momelotinib versus fedratinib safety in myelofibrosis
-
0:45
difference between quality of life & patient-reported outcomes
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
2:41
an overview of the latest advances in hematology
-
2:04
preliminary results from the blin01 trial
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis